Carfilzomib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma: A Phase I Trial-Reference-Cited by-同舟云学术

Carfilzomib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma: A Phase I Trial

Published:2021-03 Issue:3 Volume:21 Page:139-146
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Kambhampati Swetha^ORCID,Fakhri Bita,Ai Weiyun Z.,Kaplan Lawrence D.,Tuscano Joseph M.,Wieduwilt Matthew J.,Sudhindra Akshay,Cavallone Erika,Reiner Jesika,Aoun Charlie,Castillo Miguel,Martinelli Michelle^ORCID,Ta Teresa,Le Diem^ORCID,Padilla Michelle,Crawford Erika,Andreadis Charalambos B.^ORCID

Funder

National Comprehensive Cancer Network

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference32 articles.

1. Impact of rituximab (rituxan) on the treatment of B-cell non-Hodgkin’s lymphoma;Dotan;P T,2010

2. Proteasome inhibition and combination therapy for non-Hodgkin's lymphoma: from bench to bedside;Mato;Oncologist,2012

3. Relapsed/refractory diffuse large B-cell lymphoma;Friedberg;Hematol Am Soc Hematol Educ Program,2011

4. Update on mantle cell lymphoma;Maddocks;Blood,2018

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Using Protein Turnover Assay to explore the drug mechanism of Carfilzomib;Acta Biochimica et Biophysica Sinica;2024-06-01

2. The Non-hodgkin Lymphoma Treatment and Side Effects: A Systematic Review and Meta-analysis;Recent Patents on Anti-Cancer Drug Discovery;2024-02

3. Drug-Loaded Biomimetic Carriers for Non-Hodgkin’s Lymphoma Therapy: Advances and Perspective;ACS Biomaterials Science & Engineering;2024-01-31

4. Canagliflozin mitigates carfilzomib-induced endothelial apoptosis via an AMPK-dependent pathway;Biomedicine & Pharmacotherapy;2023-08

5. Clinical Experience on Proteasome Inhibitors in Cancer;Precision Cancer Therapies, Volume 1 ‐ Targeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies;2023-03-15